High Falls Canna New York

High Falls Canna New York concentrated its July 2026 revenue in Flower at 64.27% share with 5.57% year-over-year growth and a 1.01% month-over-month lift, while Pre-Roll held 18.30% share with a 19.88% month-over-month increase but a 1.22% year-over-year decline. Tincture & Sublingual captured 10.41% share despite a 30.26% year-over-year drop and a 5.22% month-over-month rise, and Concentrates expanded year-over-year by 233.26% but contracted 15.32% month-over-month at a 6.36% share. Minor categories moved at the margins: Edible fell 95.73% year-over-year yet rebounded 43.38% month-over-month to 0.40% share, and Topical declined 67.86% year-over-year with a 14.89% month-over-month uptick to 0.25% share. Taken together, the mix indicates a tilt toward inhalables with Flower stability and Pre-Roll momentum offsetting wellness category erosion, which helps explain a modest brand-level year-over-year sales decline of 5.96% alongside a 5.28% year-over-year drop in average price.

Positioning-wise in New York, the 64.27% Flower weight paired with a rank of 48 in Flower suggests reliance on a large but competitively stratified segment, where a 1.01% month-over-month gain must counteract pricing pressure from a 5.28% brand average price decline year-over-year. The 19.88% month-over-month surge in Pre-Roll provides short-cycle volume insurance against Tincture & Sublingual’s 30.26% year-over-year contraction, but the 15.32% month-over-month dip in Concentrates after a 233.26% year-over-year jump signals volatility that limits dependable contribution. The implication is a near-term need to deepen share in core Flower while converting Pre-Roll’s month-over-month growth into sustained share gains, using selective price architecture to mitigate the brand’s 5.96% year-over-year sales contraction without overexposing lower-growth wellness formats.